Publicaciones en las que colabora con José Ramón González Juanatey (48)

2024

  1. Biocompatibility Testing of UV-Curable Polydimethylsiloxane for Human Umbilical Vein Endothelial Cell Culture on-a-Chip

    ACS Omega, Vol. 9, Núm. 28, pp. 30281-30293

  2. Continuidad asistencial entre cardiología y AP en pacientes con cardiopatía isquémica crónica: diseño del estudio CAPRICI

    REC: CardioClinics

  3. Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

    Diseases, Vol. 12, Núm. 10

  4. Edoxaban treatment in a post-infarction experimental model

    European Journal of Pharmacology, Vol. 962

2023

  1. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593

  2. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase

    Primary Care Diabetes, Vol. 17, Núm. 4, pp. 366-372

  3. Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

2022

  1. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252

  2. Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers

    Scientific Reports, Vol. 12, Núm. 1

  3. The Role of Fatty Acid-Binding Protein 4 in the Characterization of Atrial Fibrillation and the Prediction of Outcomes after Catheter Ablation

    International Journal of Molecular Sciences, Vol. 23, Núm. 19

2021

  1. Estudio observacional, multicéntrico y prospectivo para evaluar los cambios en la función cognitiva en pacientes tratados con iPCSK9. Protocolo de estudio

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 45, Núm. 3, pp. 150-154

  2. Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value

    Journal of Molecular Medicine, Vol. 99, Núm. 12, pp. 1741-1753

2019

  1. A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population

    International Journal of COPD, Vol. 14, pp. 371-380

  2. Ablation of atrial fibrillation in patients with Brugada syndrome: A systematic review of the literature

    Journal of Arrhythmia, Vol. 35, Núm. 1, pp. 18-24

  3. Inflammatory effects of in vivo glycated albumin from cardiovascular patients

    Biomedicine and Pharmacotherapy, Vol. 113

  4. Obesity-Related Genetic Determinants of Heart Failure Prognosis

    Cardiovascular Drugs and Therapy, Vol. 33, Núm. 4, pp. 415-424

  5. The different roles for the advanced glycation end products axis in heart failure and acute coronary syndrome settings

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 29, Núm. 10, pp. 1050-1060

2018

  1. Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium

    British Journal of Clinical Pharmacology, Vol. 84, Núm. 2, pp. 280-291

  2. Relevance of Dementia in Atrial Fibrillation Patients within a Specific European Health Care Area

    Neuroepidemiology, Vol. 51, Núm. 1-2, pp. 11-18

  3. Validating Left Atrial Low Voltage Areas During Atrial Fibrillation and Atrial Flutter Using Multielectrode Automated Electroanatomic Mapping

    JACC: Clinical Electrophysiology, Vol. 4, Núm. 12, pp. 1541-1552